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Objective: To investigate the importance of monocyte recruitment in thrombus resolution and the role of cysteine-
cysteine (CC) chemokines and the CC chemokine receptor, CCR2, in this process.
Methods: Peritoneal macrophages, monocyte chemotactic protein 1 (MCP1), or carrier solutions were injected into
thrombi induced in the vena cava of rats. Caval thrombi were also formed in CCR2/ and MCP1/ mice and in
wild-type mice transfected with an adenoviral construct expressing a broad-spectrum CC receptor antagonist.
Results: Direct administration of peritoneal macrophages decreased thrombus size by more than fivefold and
increased recanalization by more than fourfold compared with controls (P < .001). A 100-ng MCP1dose reduced
thrombus size by more than sixfold (P < .01) and increased recanalization by more than sevenfold (P < .01), without
affecting macrophage recruitment. Deletion of CCR2 or blockade of all CC chemokines inhibited both monocyte
recruitment (P < .05) and thrombus resolution (P < .01), but knocking out MCP-1 had no effect.
Conclusion: Increasing macrophage numbers in the thrombus enhances its resolution. MCP1 treatment enhances
resolution by stimulating recanalization, independent of an effect on monocyte recruitment. CCR2 deficiency has the
same effect as blockade of all CC chemokines. CCR2 receptor activation may therefore be an important mechanism
in monocyte recruitment into venous thrombi and could be targeted to promote their resolution. (J Vasc Surg 2006;43:
601-8.)
Clinical Relevance: Deep vein thrombosis may lead to residual venous obstruction or reflux and result in post-thrombotic
complications, which are debilitating and have a substantial socioeconomic impact. Enhancing the resolution of venous
thrombi may reduce post-thrombotic complications.The rapid and complete resolution of deep venous
thrombosis may conserve valve integrity and, as a conse-
quence, reduce the incidence of post-thrombotic syn-
drome.1 Incomplete resolution of the thrombus encourages
rethrombosis, further propagation, and valve destruction.
Valvular incompetence and obstruction is ultimately re-
sponsible for ambulatory venous hypertension and cutane-
ous ulceration.2
Anticoagulation diminishes thrombus propagation, the
risk of rethrombosis, and life-threatening thromboembo-
lism. Anticoagulants do not, however, promote thrombus
resolution.3 The use of systemic and local thrombolytic
treatment is effective in reducing thrombus burden but is
complicated by a risk of hemorrhage.4 Thrombolytic agents
remove thrombus rapidly in patients with proximal il-
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doi:10.1016/j.jvs.2005.10.073eofemoral thrombi who are treated early. They can restore
luminal patency and maintain distal valve function, but
their use also carries a risk of major bleeding and has not
been widely adopted in the United Kingdom.
Venous thrombus resolves by a process of organiza-
tion and recanalization that is similar to the formation of
granulation tissue in healing wounds. The recruitment of
inflammatory cells is an important component of both
processes. An initial neutrophil infiltrate is replaced by
monocyte-derived macrophages5-7 that have the capacity
to express a host of chemotactic agents, proteases, and
growth factors that orchestrate tissue remodelling and re-
vascularization.8,9 Our previous studies have shown that
monocytes are recruited in large numbers into maturing
human and experimental venous thrombi thrombi,6 and
thrombus resolution does not occur if their recruitment
is restricted.10 Monocyte chemoattractants such as the
cysteine-cysteine (CC) chemokine, monocyte chemotactic
protein-1 (MCP1), are also expressed in the thrombus as it
organizes, and treatment with exogenous MCP1 enhances
resolution,11,12 although evaluation of monocyte recruit-
ment was not assessed.11 These data suggest that increasing
monocyte recruitment into the thrombus might improve
its resolution.
The aim of this study was to determine whether en-
hanced thrombus resolution could be achieved by increas-
ing thrombus macrophage numbers through either the
direct injection of isolated macrophages or by stimulating
their ingress with the addition of MCP1. The importance
of the endogenous expression of MCP1, its cognate recep-
tor, CCR2, and the CC chemokine system was also inves-
601
JOURNAL OF VASCULAR SURGERY
March 2006602 Ali et altigated by using gene knockout mice and a selective CC
chemokine inhibitor.
MATERIALS AND METHODS
Rat and mouse models of venous thrombosis. This
project was carried out in accordance with the United
Kingdom Animal (Scientific Procedures) Act 1986. Lami-
nated thrombus was produced in the inferior vena cava
knockout mice and their wild types13,14 by using previously
described flow models of venous thrombosis.6,15
Analysis of the thrombus
Measurement of thrombus size. Digital images of
hematoxylin and eosin stained sections of thrombi were
taken at 50 magnification (Nikon Coolpix 990). Acqui-
sition, spatial calibration, and analysis of captured images
were achieved, in a blinded manner, using Image-Pro Plus
analysis software (Media Cybernetics UK, Berkshire, UK).
Thrombus size was estimated by measuring the cross-
sectional area of thrombus in sections taken at defined
intervals (500 m in the rat and 300 m in the mouse) and
adding the areas obtained along the entire length of the
specimen. Thrombus volume was estimated by multiplying
the mean cross sectional area by the length of the thrombus.
Measurement of recanalization area of thrombus.
Recanalizing channels were identified as spaces, lined by flat
endothelial-like cells, found between resolving thrombus
and the vein wall and within the main body of the throm-
bus. Cross-sectional images were taken and analyzed as
described above. The area of recanalization was measured
in each section and expressed as a percentage of the luminal
area of the vein. This allowed estimation of the total per-
centage recanalization for each thrombus. We have previ-
ously examined the interoperator variability of this method
and found this to be 10%.12
Measurement of macrophage content. Rat throm-
bus. The endogenous peroxidase activity in sections was
quenched by immersing dewaxed paraffin sections for 10
minutes in a solution of 1% hydrogen peroxide in metha-
nol. The rat macrophage CD68 antigen was retrieved by
pressure-cooking sections in 0.01M citrate buffer (pH 6.0)
for 2 minutes. Sections were blocked with 10% normal
horse serum in Dulbecco phosphate-buffered saline
(DPBS) containing 0.01% bovine serum albumen. CD68
expression was located using 5 g mouse antirat CD68
antibody (ED1, Serotec, Oxford, UK). A secondary rat
adsorbed biotinylated horse antimouse immunoglobulin G
(IgG) (Vector Laboratories, Peterborough, UK), avidin-
biotinylated peroxidase complex (Vectastain Elite ABC,
Vector), and SG chromogen (Vector) were then used to
detect primary antibody binding. Sections were counter-
stained with Nuclear Fast Red (Vector).
Mouse thrombus. Antigen retrieval was done on paraffin
sections of mouse thrombus as described above. Sections
were blocked with serum-free Protein Block (Dako, Ely,
Cambridgeshire, UK) and the mouse macrophage marker,
Mac3, located using a rat antimouse Mac3 antibody (BD
PharMingen, Oxford, UK). A rabbit antirat IgG and theVectastain ABC reagent (Vector) were used to detect pri-
mary antibody binding as described above. The macro-
phage content of the thrombus was measured as the per-
centage area of the thrombus stained by the ED1 or Mac3
antibodies. Digitized images were taken and analyzed as
described above.
Generation and characterization of peritoneal
mononuclear cells. Three donor rats were given an intra-
peritoneal injection (20 mL/kg) of 2-month-old, 4%
sterile thioglycollate broth (Biotec Laboratories Ltd, Suf-
folk, UK). This induced a macrophage-rich exudate that
was recovered by peritoneal lavage with 40 mL sterile
DPBS 5 to 7 days after thioglycollate administration.16 The
lavage fluid was pooled, centrifuged at 400g for 5 minutes
at room temperature, and the recovered peritoneal cells
were washed twice with sterile DPBS containing 1% bovine
serum albumin. The cell pellet was then prepared for dif-
ferential cell count, flow-cytometric, and immunohisto-
chemical analyses (ED1) (Serotec).
Flow-cytometric analysis of peritoneal lavage fluid
cell populations. The monocytic cell population in the
pooled lavage fluid was quantified by differential expression
of CD3 and CD4, because conventional antirat monocyte
antibodies such as ED1 are not informative in flow cyto-
metric analysis. Cells were first blocked with mouse antirat
Fcii receptor (BD PharMingen). CD3 and CD4 antigens
were visualized using mouse antirat CD3 (R-Phycoerythrin-
conjugate) and CY-Chrome-conjugated antirat CD4 anti-
bodies (BD PharMingen). Flow-cytometric analysis was
performed on a FACScan flow cytometer (Becton Dickin-
son UK Ltd, Oxford, UK). Gating was based on forward
and side scatter characteristics.
Differential and viability counts of lavage cells. Lavage
smears were stained by using the conventional Wright-
Giemsa method. A standard 200-cell differential count was
carried out by two independent observers, and the percent-
age number of macrophages was determined. The percent-
age number of viable cells was measured in a Neubauer
hemocytometer by using the trypan-blue dye exclusion
technique.
Immunohistochemical analysis peritoneal lavage
macrophage content. Lavage fluid containing1104 cells/
100 L was spun onto Vectabond (Vector) coated slides
(cytospin) at 900g for 10 minutes and allowed to air-dry.
Rat Fc blocking antibody (2 g anti-rat CD32/Fcii re-
ceptor) (BD PharMingen) was applied for 5 minutes at
room temperature, and the cells were fixed and permeabil-
ized using IntraPrep reagent (Immunotech, Marseille,
France) for 15-minutes. The slides were washed in PBS,
and endogenous peroxidase was quenched in a solution of
1% hydrogen peroxide inmethanol. The slides were washed
in distilled water, and Protein Block (Dako) was applied for
5 minutes at room temperature. The rat macrophage
marker (ED1) was detected by using 5gmouse antirat ED1
(Serotec). Primary antibody binding was located with the
Envision detection kit (Dako) and SG chromogen (Vector).
Fibrinolytic activity of lavage cells. The fibrinolytic
activity of the lavaged cells was measured by incubating the
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(Chromagenix S-2403) and lys-plasminogen (a gift from
Prof P Gaffney, NIBSC, UK). The optical density of this,
and a series of uPA standards or blank controls, was mea-
sured at 405 nm.
Peritoneal-derived mononuclear cell injection into
thrombus. Caval thrombi were induced in a cohort of
eight rats. DPBS (50 L) containing about 2  107 peri-
toneal lavage mononuclear cells was injected directly into
the thrombus 48 hours later. Thrombus formed in a second
group of eight animals was injected with the same volume
of DPBS carrier alone. The rats were killed after 7 days, and
the vena cavae containing the thrombus were harvested.
Specimens were fixed in 4% formalin and embedded in
paraffin. Thrombus size, recanalization, and macrophage
content were measured in 5-m sections taken at 500-m
intervals throughout the length of the specimen, as de-
scribed above.
The fate of MCP1 protein injected into formed
thrombus. A thrombus was formed in the vena cava of
four groups of three rats each. Twenty-four hours after
thrombus induction, 1 Ci of 125I-MCP1 (Amersham,
Little Challfont, Oxon, UK) was directly injected into the
thrombus of each animal by using a gas tight Hamilton
syringe and 36-guage needle. Rats were killed after 3 hours,
1 day, 3 days, and 7 days, and samples of blood, caval wall,
thrombus, aorta, heart, lung, spleen, liver, and skin were
taken. All tissues were rinsed in DPBS. The amount of radio-
activity they contained counted on a gamma counter (LKB,
Turku, Finland). The counts were expressed as a percent-
age of the total count used and normalized for the wet
weight of the sample.
The effect of MCP1 on venous thrombosis
resolution. Caval thrombus was induced in four groups
of eight rats. Doses (10 L) of 1000 ng, 100 ng, or 33 ng
of recombinant rat MCP1 (Serotec, UK) were injected
directly into the thrombus formed in three groups of ani-
mals 48 hours after induction of thrombus. An equal vol-
ume of carrier (DPBS) was injected in the fourth cohort to
act as a control. The rats were killed 7 days later, and the
length of cava from the left renal vein to the iliac bifurcation
was harvested. Each specimen was rinsed in DPBS solution,
fixed in 4% formalin, and embedded in paraffin. Thrombus
size, recanalization, and macrophage content were mea-
sured in 5-m sections taken at 500-m intervals through-
out the length of the specimen, as described above.
Natural thrombus resolution in MCP1/ and
CCR2/ mice. Thrombosis was induced in the vena
cavae of four groups of control and knockout-MCP1/
and CCR2/ mice (n  48/group). Mice were killed at
3, 7, 14, and 21 days, and the vena cavae containing the
thrombus were harvested, washed in sterile PBS, fixed in 4%
formalin solution, and embedded in paraffin. Thrombus
size, recanalization, and macrophage content were mea-
sured in 5-m sections taken at 300-m intervals through-
out the length of the specimen, as described above.Generation of adenovirus construct expressing35Kd protein (ad.35K). An adenoviral construct con-
taining the 750 bp fragment of 35K of the vaccinia virus
(Lister strain), incorporating a carboxy-terminal HA epitope
tag, was produced as described previously.17 A recombinant
adenovirus, ad.35K, was generated after transfection of 293
cells using the AdEasy system (Stragene, La Jolla, CA).18 A
control recombinant adenovirus, containing the gene en-
coding enhanced green fluorescence protein (ad.EGFP,
Clonetech, Mountain View, Calif) was used as a control for
viral infection and was also prepared as described above.
Viruses were isolated and purified as previously described. 19
Assessment of cell migration. A modified Boyden
chamber assay with transwell membranes (6.0-mm diame-
ter, 8-m pore size) (Receptor Technologies, Adderbury,
Oxon, UK) was used to assess specific CCR5 receptor-
directed cell migration, as previously described.17 Briefly,
293 cells were grown to 50% confluence in Dulbecco
modified Eagles media (DMEM) and 10% (v/v) fetal calf
serum. The cells were then co-transfected (Fugene6,
Roche, Lewes, East Sussex, UK) with plasmids encoding
CCR5 and enhanced green fluorescence protein (EGFP) to
facilitate localization. Transfected cells were harvested and
allowed tomigrate overnight towards serum samples placed
in the lower chamber. Cells that migrated to the underside
of membranes were fixed and quantified by computer anal-
ysis of EGFP fluorescence in confocal microscope images.
Each experimental sample was analyzed in duplicate, and
three separate images were quantified for each membrane.
Confirmation of adenoviral construct transfection.
Indirect confirmation of construct expression was carried
out by fluorescence microscopy on sections of liver taken
from animals treated with the control ad.EGFP. Direct con-
firmation of 35K expression in the plasma of ad35K treated
animals, was carried out byWestern blotting. Plasma, taken
2 weeks after injection, was incubated for 2 hours with
monoclonal anti-HA agarose conjugated beads (Sigma,
Gillingham, Dorset, UK). The beads were washed, diluted
1:1 in 2 sodium dodecyl sulfate (SDS) sample buffer and
the proteins denatured by heating at 95°C for 3 minutes.
Beads were pelleted by centrifugation and the supernatant
separated on 14% SDS-polyacrylamide gel electrophoresis
gels. After transfer to polyvinylidene fluoride membranes,
35Kd protein was detected using rat monoclonal anti-HA
high affinity antibody (Roche) followed by an anti-rat
secondary antibody conjugated to horseradish peroxidase.
CC chemokine blockade, monocyte recruitment,
and thrombus resolution. Two cohorts of ten 8- to
12-week-old wild-type mice were injected with ad.35K or
ad.EGFP (1  109 plaque-forming units in 300 L sterile
PBS) through the tail vein. The mice were anesthetized
48 hours after the injection, and thrombosis was induced in
their vena cavae as described above. The mice were killed 2
weeks after thrombus induction, and thrombus and blood
(ethylenediamine tetraacetic acid anticoagulant) were col-
lected. The thrombus was washed in sterile PBS, fixed, and
embedded in paraffin. Thrombus size, recanalization, and
macrophage content weremeasured in 5-m sections taken
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Statistical analysis. Data are presented as means 
standard error of the mean (SEM). Intergroup differences
were determined by the Student’s t test or the Mann-
Whitney U test, as appropriate. Differences in the MCP1
dosing experiments were analyzed with one-way analysis of
variance (ANOVA) with post-test analysis (Tukey multiple
comparison test). Differences between control and knock-
out mice resolution curves were analyzed by using two-way
ANOVA. All data were analyzed with PRISM (version 3)
statistical software (GraphPad Software, San Diego, Calif).
A P  .05 was accepted as significant.
RESULTS
Characteristics of thioglycollate-induced peritoneal
macrophages. Cell viability was 80%. At least 75% of
the recovered cells were of a mononuclear cell phenotype
and the remaining cells were polymorphonuclear in mor-
phology as determined by Wright-Giemsa staining. Flow-
cytometric and immunohistochemical analyses showed
that 65% of the gated events were CD4	/CD3 cells
(Fig 1, A), and 70% of the cells were ED1	 (Fig 1, B).
The cells generated fibrinolytic activity that was equivalent
to just over 1ng/mL of urokinase activity.
Intrathrombus injection of peritoneal macrophages.
Significantly greater numbers of macrophages (ED-1	
cells) were found in treated animals compared with controls
(37.5%  2.4% vs 27.5%  3.1% at 7 days, P  .05).
Thrombus size was reduced by over fivefold compared with
controls (12.1  1.7 mm3 vs 63.3  7.3 mm3, P  .001),
and thrombus recanalization was more than fourfold
greater in animals treated with peritoneal-derived macro-
phages compared with controls (14.1%  1.4% vs 3.1% 
0.7%, P  .001).
Intrathrombus injection ofMCP1. 125-I-MCP1 was
predominantly found in the thrombus at all the time inter-
vals studied (Fig 2). Levels of 125-I MCP1 were greatest
3 hours after injection, but significant amounts were still
present after 7 days. Radioactivity was also found in the
vena cavae of treated animals, but was not detectable in
other tissues (blood, aorta, lung, spleen, liver, or skin).
Effect on thrombus resolution. Treatment with
MCP1 resulted in a reduction in thrombus volume com-
pared with controls (P  .001, ANOVA) (Fig 3, A). All
three doses significantly reduced thrombus size compared
with control (P  .05). The dose effect was greatest after
injection with 100 ng MCP1 (9.8  3.0 mm3 vs 63.3 
7.3 mm3 in controls, P  .001). Thrombus macrophage
content did not differ from controls in any of the MCP1-
treated groups (P  0.1, ANOVA).
Treatment with MCP1 increased thrombus recanaliza-
tion (P  .002, ANOVA) (Fig 3, B). This difference was
significant at the 30- and 100-ng doses (P .01), with the
greatest response achieved at 100 ng of MCP1 (22.4% 
4.0% vs 3.1%  0.7%, P  .01). Treatment with 1000 ng
MCP1 also increased the recanalization of thrombi com-pared with control, but this failed to reach statistical signif-
icance (6.8%  2.0% vs 3.1%  0.7%; P  .05).
Monocyte recruitment and thrombus resolution in
MCP-1/ and CCR2/mice. A similar temporal pat-
tern of resolution was observed inMCP1/ and wild-type
controls (Fig 4, A). The size of thrombus produced in
CCR2/ mice was not significantly different from their
wild-type controls (10.7  1.9 mm3 vs 11.1  1.9 mm3;
P  .89), but subsequent resolution of the thrombus was
significantly delayed in CCR2/ mice compared with
wild-type controls (P  .001, ANOVA, Fig 4, B). Signifi-
cant differences in thrombus size were evident at 7, 14, and
21 days (P  .05), although by 21 days this difference was
Fig 1. A, Fluorescence activated cell sorting analysis of peritoneal
lavage cells demonstrates the CD4	/CD3 macrophage popula-
tion in the upper left-hand quadrant. B, Peritoneal lavage fluid
cytospin shows an abundance of mononuclear cells (arrows)
stained by the rat macrophage marker, ED1 (brown stain, 100
original magnification).small.
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lower in the CCR2/ mice than in their wild-type con-
trols at day 7 (0.5% 0.02% vs 0.63% 0.02%; P .006)
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Fig 3. Dose effect of monocyte chemotactic protein 1 (MCP1)
(ng) on (A) recanalization and (B) thrombus size 7-days after
thrombus induction. Values are  SEM.
blood IVC thrombus aorta
0.00
0.05
0.10
0.15
0.20
0.25
0.30
lo
g
   
c
o
u
n
ts
 / 
g
ra
m
   
ti
s
s
u
e
Fig 2. 125I-monocyte chemotactic protein 1 distributi
thrombus. IVC, Inferior vena cava.and day 14 (0.5%  0.02% vs 0.61%  0.02%; P  .009).CC chemokine system blockade. Widespread expres-
sion of EGFP was detected in the liver parenchyma of the
ad.EGFP-transfected mice (Fig 5, A). Detection of the
35Kd protein by Western blotting of plasma from animals
injected with ad.35K mice indicated successful viral trans-
fection. No protein could be detected in plasma taken from
ad.EGFP-treated controls (Fig 5, B). Plasma obtained from
ad.35K transfected mice almost halved the in vitro migra-
tion of CCR5-transfected 293 cells compared with plasma
from ad.EGFP-treated mice (1193  68 cells vs 1994 
385 cells, P  .037).
Macrophage recruitment in 2-week-old venous thrombi
was significantly reduced in ad.35K-infected animals
(0.55% 0.03%) compared with controls (0.47% 0.01%;
P  .036). The residual thrombus volume was more than
fivefold greater in ad.35K-infected animals (2.59  0.62
mm3) compared with controls (0.51  0.22 mm3, P 
.005) (Fig 6).
DISCUSSION
Increasing the numbers of macrophages by direct in-
jection of fibrinolytically active peritoneal cells into the
thrombus resulted in a large reduction in thrombus size and
an increase in recanalization. Although the peritoneal la-
vage fluid contained predominantly macrophages, it did
contain significant numbers of other leukocytes, mainly
polymorphonuclear cells, which may have influenced reso-
lution. Neutrophils, for example, express a variety of en-
zymes (urokinase, cathepsin G, and elastase) that can de-
grade fibrin,20 and spontaneous lysis has been observed in
polymorphonuclear-enriched thrombi produced in vitro.21
These cells also secrete matrix metalloproteinases such as
MMP9 and angiogenic cytokines such as interleukin 8 that
influence angiogenesis and tissue remodelling.22,23
Treatment of experimental venous thrombi with
MCP1 at doses between 30 ng and 1000 ng significantly
reduced thrombus size, which is in agreement with our
original pilot data in which a 1000-ng dose was used.11 A
kidney lung liver skin spleen
3 hrs
1 day
3 days
7 days
rat tissues for up to 7 days after direct injection intoheart
on inmaximal effect (more than sixfold reduction in thrombus
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with a lesser effect at the higher dose. The reason for this
nonlinear response is not clear, but a similar effect has been
reported for cells treated with vascular endothelial cell
growth factor (VEGF) in vitro24 and thrombus treated
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Fig 4. A, Longitudinal study of thrombus resolution inMCP/
mice (grey circles) and wild-type controls (black circles) and in (B)
CCR2/mice (grey circles) and wild-type controls (black circles).
*Denotes intergroup significance (P  .05). Values are  SEM.
ANOVA, Analysis of variance.
Fig 5. A, Section of liver from ad.EGFP-treated mouse showing
successful gene adenoviral transfection and EGFP expression
(green fluorescence arrows, 100 original magnification). B,
Western blot of from five ad.35K transfected mice. The 35K
protein and plasma from ad.EGFP treated animal were used as
positive and negative controls respectively.with VEGF in vivo.12The effect of MCP1 was, however, independent of
monocyte numbers, as increasing MCP1 levels in the
thrombus did not lead to enhanced monocyte recruitment.
This dissociation between increased local or circulating
MCP1 levels andmonocyte chemotaxis has previously been
demonstrated in MCP1 over-expressing mice.25 Our pre-
vious work has also shown that the thrombus contains
comparatively lower levels of MCP1 during natural resolu-
tion.26 Treatment with a high MCP1 dose may have over-
whelmed the subtle chemotactic gradient that exists in vivo.
Although the amount of MCP1 remaining within the
thrombus after injection was not quantified, tracking stud-
ies demonstrated measurable amounts of labelled MCP1
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Fig 6. The effect of vaccinia virus-derived 35Kd protein blockade
of C-C chemokines on (A) thrombus size and (B) thrombus
recanalization harvested 14 days after tail vein gene transfer.remaining in the thrombus for at least 7 days. Only very
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tissues and the viscera. These data are consistent with the
distribution of other injected radiolabeled cytokines, such
as VEGF, that we have previously used in this thrombus
model.26
It is probable that MCP1 enhanced thrombus resolu-
tion by stimulating recanalization, as treatment with this
cytokine caused a more than a sevenfold increase in the
recanalization area; but the mechanisms by which MCP1
regulates this process in the thrombus remain to be defined.
MCP1 can promote angiogenesis through a direct action
on endothelial cells27 and can stimulate macrophages to
form vascular channels or express potent angiogenic growth
factors such as VEGF.28,29 Increased thrombus recanaliza-
tion may, however, be stimulated by angiogenic cytokines
without any effect on thrombus size.30 Improved throm-
bus contraction has been reported after treatment of the
thrombus with angiogenic cytokines such as basic fibroblast
growth factor.30 It is possible, therefore, that MCP1 may
have stimulated thrombus recanalization in a similar man-
ner in this study.
Deletion of theMCP1 gene had no effect on monocyte
recruitment and thrombus resolution. This was not surpris-
ing, as a high degree of redundancy and promiscuity is
known to exist between CC chemokines and their recep-
tors.31,32 Deletion of MCP1 may have simply resulted in
the upregulation of other MCPs (MCP2, 3, and 4) and CC
chemokines, which replaced the activity of MCP1. The
design of this study centred, however, around histologic
and image analytic end-points that were not amenable to
the measurement of changes in the expression of other
MCPs and chemokines. Blockade of all members of the CC
chemokine family with a vaccinia-derived 35Kd protein,
which has been shown to decrease monocyte recruitment
into aortic plaques in mice,17,33 also inhibited monocyte
recruitment into thrombus and reduced thrombus resolu-
tion and recanalization in this study. The effects of block-
ade by the 35K protein were, however, no greater than
those seen in the CCR2/ mice, in whom there was also
a reduced monocyte ingress and a marked delay in throm-
bus resolution. These data suggest that CCR2 activation is
an important mechanism in the regulation of monocyte
migration into thrombus.
Deletion of the gene encoding the CXCR2 receptor,
which regulates neutrophil chemotaxis, has been shown to
reduce both neutrophil and monocyte recruitment into the
thrombus, which causes an initial delay in thrombus reso-
lution that is lost after 8-days.22 It is not clear, however,
whether this effect was the result of a direct action on
monocyte chemotaxis or whether decreased neutrophil
signalling caused a subsequent reduction in monocyte re-
cruitment.
CONCLUSION
The findings of this study support the concept that the
monocyte/macrophage is a key mediator of venous throm-
bus resolution6,10 and suggests that the CC chemokine
family and their receptors have an important role in thecomplex process that regulates their recruitment. Targeting
of this receptor family with novel agonists may form the
basis of a treatment that accelerates the resolution of venous
thrombi and minimizes the effects of the post-thrombotic
syndrome.
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